Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Settles PCR Litigation with Takara Bio

NEW YORK, May 12 (GenomeWeb News) - Stratagene and Takara Bio have settled a patent disputes related to PCR enzyme blends, Stratagene said today in an 8-K filing with the US Securities and exchange Commission.


As a result of the settlement, "all pending litigation over patent issues in the US District Court for the District of Maryland and in the US Patent & Trademark Office will be dismissed," Stratagene said. "Potential disputes in the future will be avoided through cross-licenses of the parties' respective patent rights relating to enzyme blends."


Stratagene did not disclose the financial details of the settlement, but said that each company "believes the principal, direct financial effect of the settlement will be the avoidance of the costs and risks of continued litigation."


The firms have agreed to pay "reasonable" royalties to each other under certain licensed patents, and each company will be free to independently license its patents to third parties.